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INTRODUCTION: 
The modulation of immune system activity is a required 
pharmacological intervention for many medical conditions. 
Immunosuppression is integral to the treatment of 
autoimmune diseases and allergies, and the inhibition and 
prevention of immune responses also constitutes a 
prominent treatment aim for transplant recipients. 
Conversely, immune system stimulation is adopted for a 
number of infect ions and cancers. With traditional 
immunomodulatory drugs continuing to exhib it limited 
efficacy and adverse side effects, the drive to develop new, 
improved, and specifically targeted immunotherapy. 
The modulation of immune system activity is a required 
pharmacological intervention for many medical conditions. 
Immunosuppression is integral to the treatment of 
autoimmune diseases and allergies, and the inhibition and 
prevention of immune responses also constitutes a 
prominent treatment aim for transplant recipients. 
Conversely, immune system stimulation is adopted for a 
number of infect ions and cancers. With traditional 
immunomodulatory drugs continuing to exhib it limited 
efficacy and adverse side effects, the drive to develop new, 
improved, and specifically targeted immunotherapies has 
been gaining momentum.
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DIS EAS ES PATTERN IN WHICH IMMUNO-
MODULATORS US E: 
Immunomodulators in the treatment of psoriasis: 
Psoriasis is a common skin d isorder characterized by 
erythematous scaly plaques. Recently, it has been realized  
that psoriasis is an inflammatory T-cell mediated disorder. 
Many recent therapeutic advances are attempting to control 
the expression of psoriasis by suppressing T-cell mediated 
inflammat ion. 
Cyclosporine and related drugs, which are effective in the 
treatment of psoriasis, was the key to the development of 
the concept that psoriasis is an immune mediated disorder. 
These therapies demonstrably reduce the number of 
activated T-lymphocytes, which correlates with clinical 
remission. Monoclonal antibodies directed against key 
components of the inflammatory process have been studied 
in an attempt to produce safer, more effective and selective 
immunosuppressive agents .
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Langerhans cell maturat ion (activation) 
 
T-cell activation, d ifferentiation and expansion of type 1 T-cell 
 
Selective trafficking of act ivated T-cell to skin  
 
Induction of an inflammatory cytokine and chemokine cascade in skin lesion 
 
Accelerates the growth of epidermal and vascular cells in psoriasis lesions 
Figure 1: Critical steps in the immunopathogenesis of psoriasis and sites of intervention of biologic therapeutics  
ABSTRACT: 
Immunomodulators are substances that have been shown to modify the immune systems response to a threat upon it. They 
modulate and potentiate the weapons of your immune system keeping them in a highly prepared state for any threat it may 
encounter. With this balancing effect, all subsequent immune responses improve. When your immune system is in this 
highly prepared state, the invading organisms do not have the time to build up force and strength before the immune 
system attacks destroys and/or weakens the invader. 
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Figure 2: Molecules associated with T-cell activation (site of action of mycophenolate mofet il and leflunomide), 
proliferation and differentiat ion
2 
A T-cell interacts with a mature Langerhans cell to become 
activated as shown in figure 2. Here the various  receptors 
involved andcytokines released are the sites of action of 
various biologics (TCR stands for T-cell receptor, MHC-I 
and II for major histocompatibility complex molecules on 
antigen presenting cells [Langerhans cells], LFA-1 for 
lymphocyte function-associated antigen-1, LFA -3 for 
lymphocyte function-associated antigen-3, ICAM-1 for 
intercellular adhesion molecu le-1, IL-12 for interleukin-12, 
IL-2 for interleukin-2 [inh ibited by cyclosporine], IL-12R 
for interleukin-12 receptor, IL-2R for interleukin-2 
receptor [inhib ited by cyclosporine], CT LA4 for cytotoxic 
T lymphocyte antigen-4, IFN- γ for interferon-gamma, 
TNF-α for tumor necrosis factor-alpha [blocked by 
infliximab or etanercept], CD8, CD3, CD4, CD80, CD86, 
LFA3, CD40, CD 28, CTLA4, CD2, CD40L [site of act ion 
of monoclonal based therapies] are various receptors on 
CD+ cells and Langerhans cells. 
Cyclosporine is a powerful immunosuppressive drug with 
no appreciable effect on the bone marrow.  
Leflunomide has demonstrated antiviral, antitumorigenic, 
and immunosuppressive properties. Its active metabolites 
reversibly inhib it the mitochondrial enzyme dihydro-
orotate dehydrogenase, the rate-limit ing step in the de 
novo synthesis of pyrimidines. As a result, it inhibits 
autoimmune T-cell proliferation and production of 
autoantibodies by Bcells. Its clinical uses include 
rheumatoid arthritis, psoriasis vulgaris and psoriatic 
arthropathy, bullous autoimmune disorders, Wegener’s 
granulomatosis and systemic vasculit is. 
Immunomodulators for Crohn’s disease and ulcerative 
colitis:   
The first two immunomodulators to be used widely in IBD 
are azathioprine (Imuranı, Azasanı) and 6- mercaptopurine 
(6-MP, Purinetholı), d rugs that are chemically quite 
similar. They are used to maintain remission in Crohn’s 
disease and ulcerative colitis. Both have a slow onset of 
action (three to six months for full effect). Accordingly, 
they are usually given along with another faster-acting 
drug (such as corticosteroids). 
Other immunomodulators to treat IBD are cyclosporine A 
and tacrolimus, both used for organ transplantation as well. 
Cyclosporine A has a more rapid onset of action (one to 
two weeks) than azathioprine and 6-MP. It is useful in  
people with active Crohn’s disease, but only when given 
intravenously and at high doses. Both cyclosporine A and 
tacrolimus have been more effective in treating people 
with severe ulcerative colit is, and are generally given until 
one of the slower-acting immunomodulators begins to 
work or until the patient undergoes curative surgery. 
Tacrolimus can be used in Crohn’s disease when 
corticosteroids are not effective or when fistulas develop.
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Methotrexate (MTX®, Rheumatrex®, Mexate®) works 
more rapid ly than azathioprine or 6-MP, and is given by 
weekly in jections. It is an effect ive option for people with 
Crohn’s disease who have not responded to other 
treatments and cannot tolerate other immunosuppressants. 
Immunomodulators in Treating Multiple Sclerosis: 
Approved Therapies: 
The approval of three interferons-beta (IFNβ) and of 
glatiramer acetate (GA) by the US Food and Drug 
Administration (FDA) in the early 1990s was the most 
important recent advance in mult iple sclerosis (MS) 
therapy. These immunomodulators are now a first-line 
treatment of relapsing-remitting (RR) and relapsing-
progressive (RP) MS. In 2000, mitoxantrone – a cytolytic 
immunosuppressant – was approved for the treatment of 
patients with a rap idly progressive disease. A second 
immunosuppressant – natalizumab (Tysabri®) – was 
approved in November 2004. Given its remarkable 
efficacy, natalizumab appeared a promising candidate for 
the long-term treatment of RR MS. However, severe 
adverse events led to a temporary suspension of the drug 
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(February 2005 to June 2006). After its reintroduction to 
the market, natalizumab was reserved for carefully  
selected patients under strict surveillance and for a limited 
period of time. Immunomodulators are well tolerated for 
years, but their efficacy is relatively modest. 
Immunosuppressants are more effect ive, but their toxicity 
prevents long-term treatments. Numerous clinical trials 
investigate new molecu les in order to improve the efficacy 
of immunomodulators and reduce the toxicity of 
immunosuppressants.
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Experimental Therapies: 
FTY720 (Fingolimod®) 
Fingolimod® converts endogenous sphingosine into its 
phosphate form, which is a high-affin ity agonist of the 
sphingosine 1 (S1P1) receptor. Fingolimod first accelerates 
homing of lymphocytes to lymph nodes and then blocks 
egress of lymphocytes from lymphoid tissues. The 
lymphocyte sequestration in lymphoid tissues leads to a 
major decrease in T- and particularly B-cell count (25% of 
baseline values) in peripheral blood. Fingolimod also 
causes thymocyte apoptosis, inhibits vascular endothelial 
growth factor (VEGF)-induced brain capillary leakage, 
impairs dendritic cell trafficking and induces a shift from 
Th1 (pro-inflammatory) to Th2 (anti-inflammatory) 
cytokine production. It has been observed in animal 
experiments that Fingolimod strongly reduces 
transmigration of macrophages into brain parenchyma.  
Rituximab: 
 Rituximab is a monoclonal Ab binding to the CD20 
surface molecu le that induces a selective, long-lasting 
depletion of B cells that is only partially reconstituted after 
one year. 
BBR2778 (Pixantrone®): 
 Pixantrone® is an analogue of MX without severe 
cardiotoxicity. In  addition, its weaker DNA-constant 
binding and its lower stimulat ion of topoisomerase II-
mediated DNA alterations suggest a lower risk of TRAL.  
Alemtuzumab (Campath-1H®):  
Alemtuzumab, a monoclonal Ab targeting the surface 
CD52 molecule mainly expressed on T lymphocytes and 
monocytes, is a potent and selective immunosuppressant of 
cellu lar immunity leading to a complete deletion of 
lymphocytes. Monocytes and B cells return to normal 
within three months, but T-cell depletion persists for up to 
five years.
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Immunomodulators in Systemic Mycoses: 
Various biopotent molecules have been studied for their 
potential to modulate and restore impaired immune 
functions required to resist fungal infections. These 
include recombinant human cytokines including 
granulocyte colony stimulating factor (rHuG-CSF), 
recombinant human macrophage colony stimulating factor 
(rHuM-CSF), interferons etc., some of which have shown 
encouraging results. Among the various categories of 
immunomodulating agents reported so far, certain peptides 
seem to hold better promise36. Six novel peptides viz.,  
hexapeptide (89/215), glycopeptides (89/729, 90/341), 
pentapeptide (SP-5) and lipopeptides (86/450, 84/201), 
synthesized have been evaluated in CDRI for potent 
immunostimulant activity.
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Immunotherapy of Cancer:  
The active immunotherapeutic approach to treatment of 
cancer is specific and based upon the premise that tumor 
antigen are immunogenic and the host is sufficiently  
immunocompetent to mount an effective immune response 
to an autologous tumor. Theoretically, a weak or 
suppressed host immune system that had allowed the 
formation of a tumor may be overridden by active 
immunizat ion and or immunostimulation. In practice, 
vaccines composed of so-called autologous tumor extract  
have been used to treat patient with malignant melanoma  
and purified melanoma tumor-associated antigens have 
been used to elicit antibody response in melanoma 
patients. 
The specificity of immune mechanisms could be harnessed 
against tumor cells. This might use the patient's own 
immune system (immunostimulants) the transfer of  
antibodies (i.e. passive immunization) or T cells from an  
outside source. Ideally, these agents would be targeted to 
molecules expressed on the cancer cells but not on healthy 
cells. However, such tumor-specific antigens have been 
hard to find, and so many of the immune agents now in use 
do target healthy cells as well, but the hope is that these 
can later be rep laced.
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Immunostimulants: 
There is considerable evidence that cancer patients have T 
cells that are capable of attacking their tumor cells. In fact, 
it may be that the appearance of cancer is a failure of 
immune surveillance: the ability of one's own immune 
system to destroy cancer cells as soon as they appear.  
Immunostimulants are nonspecific agents that tune-up the 
body's immune defenses. There have been some successes 
with: 
 Injecting adjuvant-like agents directly into the tumor. 
The only one that succeeds often enough to remain in  
use is the bacterial preparation BCG. Introduced into 
the bladder, it can help  eradicate early-stage bladder 
tumors.  
 Oral therapy with levamisole, a drug widely-used for 
deworming (people as well as animals), has been used 
to treat a variety of cancers but with inconsistent 
results.  
 interleukin-2 (IL-2), a  potent growth factor for T cells;  
 alpha-interferon (IFN-α)  
Cancer Therapy with Monoclonal Antibodies  
A number of monoclonal antibodies show promise against 
cancer, especially cancers of white blood cells (leukemias, 
lymphomas, and mult iple myeloma). 
Some examples:  
Rituximab (trade name = Rituxan®). Used to treat B-cell 
lymphomas. The CD20 molecule to which it binds is 
present on most B-cells, healthy as well as malignant, but 
over the months following treatment, new healthy B cells 
are formed from precursors that do not have CD20 and 
thus were not destroyed by the treatment.
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Herceptin®. Binds HER2, a growth factor receptor found 
on some tumor cells (some breast cancers, lymphomas). 
The only monoclonal so far that seems to be effective 
against solid tumors.  
Alemtuzumab (MabCampath®). Binds to CD52, a 
molecule found on white blood cells. Has produced 
complete remission of chronic lymphocytic leukemia (for 
18 months and counting).  
Lym-1 (Oncolym®). Binds to the HLA -DR-encoded 
histocompatibility antigen that can be expressed at high 
levels on lymphoma cells.  
Bevacizumab (Avastin®). Binds to vascular endothelial 
growth factor (VEGF) thus blocking its action and 
depriving the tumor of its blood supply.  
Cetuximab (Erbitux®). Used to treat colorectal cancers.  
Ipilimumab. Blocks the immunosuppresive effects of 
CTLA-4. Has shown some benefit against metastatic 
melanoma.  
Immunotoxins 
A major problem with chemotherapy is the damage the 
drugs cause to all tissues where rapid cell division is going 
on. What is needed is a "magic bullet", a method of 
delivering a cytotoxic d rug directly and specifically to 
tumor cells, sparing healthy cells. Such a magic bullet  
would have two parts:  
 a monoclonal antibody specific for the cancer cell 
attached to  
 a cytotoxic drug or toxin that kills the cell once it gets 
inside.  
Many such conjugates have been tried but only two 
have found their way into anticancer therapy.  
Mylotarg®:  
 A monoclonal antibody that binds CD33, a cell-
surface molecu le expressed by the cancerous cells in 
acute myelogenous leukemia (AML) but not found on 
the normal stem cells needed to repopulate the bone 
marrow.  
 calicheamicin, a complex oligosaccharide that makes 
double-stranded breaks in DNA. 
Mylotarg® is the first immunotoxin to show promise in the 
fight against cancer.  
CAT-3888 (formerly known as BL22):  
 a monoclonal V-region antibody fragment against 
CD22, a molecule found on the surface of B-cell 
leukemias and lymphomas, with  
 Pseudomonas exotoxin, a bacterial product that blocks 
protein synthesis in cells causing them to self-destruct 
by apoptosis.  
Radioimmunotherapy 
Monoclonal antibodies against tumor antigens can also be 
coupled to radioactive atoms. The goal with these agents is 
to limit the destructive power of radiation to those cells 
(cancerous) that have been "fingered" by the attached 
monoclonal antibody.  
Examples: Zevalin®. Th is is a monoclonal antibody 
against the CD20 molecule on B cells (and lymphomas) 
conjugated to either the radioactive isotope indium-111 
(
111
In) or the radioactive isotope yttrium-90 (
90
Y). Both are 
given to the lymphoma patient, the 
111
In version first 
followed by the 
90
Y version (in each cases supplemented 
with Rituxan). Bexxar® (tositumomab). Th is is a 
conjugate of a monoclonal antibody against CD20 and the 
radioactive isotope iodine-131 (
131
I). It, too, is designed as 
a treatment for lymphoma. Although both Bexxar® and 
Zevalin® kill normal B cells, they don't harm the B-cell 
precursors because these do not express CD20. So, in time, 
the precursors can repopulate the body with healthy B 
cells.  
Cancer Therapy with T Cells  
Tumor destruction is done by cells. Antibodies may help, 
but only by identifying the cells to be destroyed, e.g., by 
macrophages. But T cells, like cytotoxic T lymphocytes 
(CTL), are designed to destroy target cells.  
Using a Bispecific Monoclonal Antibody 
Blinatumomab is a synthetic monoclonal antibody each 
arm of which carries a b inding site with a different 
specificity:  
 one arm binds to CD19, an antigen found on the 
surface of B cells and B-cell lymphomas; 
 The other arm binds to CD3, a cell-surface molecule 
on T cells, including cytotoxic T lymphocytes (CTLs).  
By fo rming a bridge between CD3 and CD19, 
blinatumomab is able to attach T cells to B cells and 
activate the T cells to kill the B cells.  
Early clin ical trials with blinatumomab on a small number 
of patients appear quite promising. Modest doses of the 
drug produced partial and, in a few cases, complete 
regression of their lymphoma.  
Allografts of T cells 
After total destruction of the patient's own white bl ood 
cells ("myeloablative conditioning") 
One approach to curing leukemia (and some other cancers) 
is to treat the patient with such high doses of 
chemotherapy and radiation that the leukemic cells are 
killed. Unfortunately, such high doses also destroy the 
patient's bone marrow. If the patient is to survive the 
treatment, he or she must be given a transplant of 
hematopoietic stem cells — the cells from which all blood 
cells are formed.  
The stem cells can be: 
 An autograft; that is, from bone marrow harvested 
from the patient and stored before treatment begins. In 
this case, however, the marrow must also be treated to 
purge it of all cancer cells it may contain before it is 
returned to the patient. This sometimes fails.  
 An allograft; that is, cells harvested from another 
person, usually a family member sharing the same 
major h istocompatibility molecules . 
Allografted hematopoietic stem cells also sometimes fail to 
cure, but in that case it is because not all of the patient's 
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leukemic cells were destroyed. However, an infusion of T 
lymphocytes from the blood of the same donor that 
provided the cells can finish off the job. Th is effect is 
called the graft-versus-leukemia effect. However, most (if 
not all) of the donor T cells are probably attacking normal 
cell surface molecules, not tumor-specific ones. (Even if 
the donor and recipient are matched for the major 
histocompatibility molecules, there will be minor ones that 
elicit a rejection response.) So the patient may also suffer 
life-threatening graft-versus-host disease (GVHD).  
Autografts of T cells: Tumor-Infiltrating Lymphocytes 
(TIL) 
Solid tumors contain lymphocytes that are specific for 
tumor antigens. For many years, Steven A. Rosenberg and 
his associates at the U. S. National Cancer Institute have 
tried to enlist these cells in cancer therapy.  
On September 19, 2002, he reported his most promising 
results to date. The procedure:  
 Isolate T cells — both CD4+ T-helper cells and CD8+ 
cytotoxic T lymphocytes  (CTL) from samples of the 
tumor (melanoma)  
 Test them in v itro to find the most efficient killers of 
the melanoma cells.  
 Grow large numbers of them in culture (using the 
powerful T-cell growth factor IL-2).  
 Treat the patient with modest doses of cytotoxic drugs 
to reduce — but not destroy — the bone marrow.  
 Reintroduce the mix of Th cells (CD4+) and CTL 
(CD8
+
) into the patient (along with IL-2).  
The results:  
 The infused cells usually took up longterm residence.  
 In 10 of 13 patients, their melanoma cells —  including 
all metastases — regressed either partially or 
completely.  
Autografts of genetically-modified T cells 
On April 20, 2006, the Rosenberg group reported some 
success with melanoma patients using a modification of 
the TIL procedure.  
The patient's T cells were removed and treated with a 
retroviral vector containing the αβ TCR specific for a 
melanoma antigen. Large numbers of these were grown in  
culture. After part ial myeloablative conditioning to "make 
room" for them, the genetically-modified lymphocytes 
were infused into the patient. This application of gene 
therapy succeeded in eliminating the metastases and 
providing a disease-free period of two years in two 
patients. 
Cancer Vaccines 
Any response of the patient's own immune system – 
immune surveillance – has clearly failed in cancer patients. 
The purpose of cancer vaccines is to elicit  a more powerful 
active immunity in the patient. Several approaches are 
being explored.  
Patient-S pecific Cancer Vaccines 
Dendritic-Cell Vaccines 
Dendritic cells are the most potent antigen-presenting 
cells. They engulf antigen, process it into peptides, and 
"present" these to T cells. 
Tumor-Antigen-S pecific Vaccines 
These vaccines are used to immunize the patient with an 
antigen universally expressed by tumors of that type (but 
not by normal cells) mixed with some form of adjuvant 
that will enhance the response.  
For example, there is growing evidence that many cancer 
patients mount an immune response — both antibody-
mediated and cell-mediated —  against the tumor antigen 
designated NY-ESO-1. Deliberate immunization with this 
protein (plus an adjuvant) boosts this response and has 
shown some promise in early clinical trials. (Cells in the 
testis do not express HLA antigens, so are not at risk from 
attack by NY-ESO-1-specific cytotoxic T lymphocytes). 
Immunomodulation in organ-transplantation; Advances in 
surgical techniques, availability of more selective 
immunosuppressant, careful patient selection, and proper 
post-surgery management are major factors in making 
transplantation the treatment of choice for end-stage organ 
failure. 
Non-specific immunosuppressive therapy in an adult 
patient is usually cyclosporine, started intravenously at the 
time of transplantation, and given orally when feed ing is 
tolerated. Typically, methylprednisone is started also at 
time of transplantation, and then reduce to a maintenance 
dose. Azathioprine may also be used in conjunction with 
prednisone to achieve adequate immunosuppression. The 
objective of immunosuppression is to protect the 
transplant, but general immunosuppression or excessive 
immunosuppression may lead to undesirable complication, 
e.g. opportunistic infections and potential malignancies. 
These adverse effects would be avoided if selective 
immunosuppression could be achieved. A number of 
Fungal Immunosuppressives have been isolated from 
fermentation broths and demonstrated to have 
immunotherapeutic efficacy. The known and most 
commonly  used is cyclosporine. Recently, two  other 
fungal metabolites, sirolimus, previously known as 
rapamycin and FK-506 are in various stages of 
development. Siro limus marked ly suppresses IL-2 or IL-4 
driven T cell proliferation. The preclinical studies suggest 
that sirolimus is a potent immuno-suppressive agent in 
transplantation and autoimmune disease models. FK-506 
interferes with IL-2 synthesis and release, and 
cyclosporine like profile, but is considerably more potent 
in vitro with IC50 value approximately 100 fold lower. 
Mycophenolate mofetil, Brequinar and Deoxyspergualin  
are in various phases of clinical eva luation. Identificat ion 
of the therapeutic efficacy and safety will be important 
factors in determination of utility as immunosuppressive 
agents.  
Treatment of keloids and hypertrophic scars: 
 Hypertrophic scars and keloids may follow local skin  
trauma or inflammatory skin disorders like laceration,  
tattoos, burns, injections, ear-piercing, vaccination, bites, 
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acne, abscess or surgery. They are the consequences of 
uncontrolled synthesis and deposition of dermal co llagen. 
The first step in minimizing scarring should be attention to 
the early care of wounds. Following recommendations are 
based on general principles of wound healing (Tab le1). 
The goal with minor wounds such as abrasions is to 
achieve rapid epithelizat ion by moist healing with 
ointment or semiocclusive dressings. When epithelizat ion 
is delayed beyond 10-14 days the incidence of 
hypertrophic scarring goes  up dramat ically. Surgical 
closure of an open wound should take into account the 
tension on the wound. Wounds  subjected to tension due to 
motion, body location, or losses of tissue (after excision of 
a lesion) are at increased risk of scar hypertrophy and 
spreading. Appropriate splinting of the tissue with 
permanent intradermal sutures should be considered. A 
useful technique is a subcuticular closure with a 
polypropylene suture that can be left in place for six 
months.
9 
Table 1:  Treatment option for keloids and 
hypertrophic scar
 
1. Pressure garments 
2. Radiat ion 
a. Superficial X-ray  
b. Electron beam therapy 
c. Interstitial radiotherapy 
3. Excision  
4. Intralesional injection  
a. Triamcinolone  
b. 5-flurouracil 
c. Bleomycin  
5. Cryotherapy 
6. Silicon gel dressings 
Biologic Therapy for Inflammatory Bowel Disease:  
Potential options for the medical management of 
inflammatory bowel d isease (IBD), part icularly Crohn's 
disease, are increasing at an unprecedented rate. In 
addition to infliximab, secondgeneration anti-tumor 
necrosis factor (TNF)-alpha agents such as adalimumab* 
and certolizumab* have shown efficacy in the induction 
and maintenance of remission in patients with Crohn's 
disease. Optimizing these medications with respect to 
timing of in itiating therapy and use of concomitant 
immunomodulators is a topic of great debate. Other 
potential agents include antibodies targeting alternate 
mechanis ms of in flammation, such as natalizumab* and 
visilizumab*. The excitement over these emerg ing agents 
is tempered by the potential toxicity, some of which is 
unique to each class of drug.
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Recently developed Immunomodulators: 
Imiquimod a recently developed imidazoquinolin  
heterocyclic amine belongs to a new class of drug, immune 
response modifier agents, which can be attributed to the 
induction of a number of cytokines including interferon-
alpha (IFN-alpha), interferon-gamma (IFN-gamma), tumor 
necrosis factor-alpha, interleukins-1, -6, -8, -12. 
Imiquimod increases in interferon and tumor necrosis 
factor in cu ltures of cells isolated from animal skin, and 
increases interleukin-8 concentrations in human 
keratinocyte and fibroblast cultures. Although in vitro 
studies have shown that imiquimod has no direct antiviral 
effects, the drug does exhib it antiviral and antitumor 
effects in vivo through induction of human cytokines. 
Although imiquimod cream recently became available for 
the treatment of genital and perianal warts, the topical 
mechanis m of action of imiquimod is not yet fully  
understood. It is believed that stimulation of local 
cytokines by imiquimod leads to a reduction in human 
papilloma virus (HPV) load; to wart regression and to the 
normalizat ion of keratinocyte proliferation without 
evidence of scarring. Treatment with topical 5 % 
imiquimod cream has shown promising results in the 
treatment of genital warts in immunocompetent 
individuals. Furthermore, it is an interesting alternative 
therapeutic method for other cutaneous viral skin lesions 
among immunocompetent and HIV-infected patients. 
 
Imiquimod 
The exact mechanism of action in which imiquimod and its 
analogs activate the immune system is not yet known. 
Nevertheless, it is known that imiquimod act ivates 
immune cells by ligating the toll-like receptor 7 (TLR7), 
commonly involved in pathogen recognition, on the cell 
surface. Cells activated by imiquimod v ia TLR-7 secrete 
cytokines (primarily interferon-α (IFN-α), interleukin-6 
(IL-6) and tumor necrosis factor-α (TNF-α)).  There is 
evidence that imiquimod, when applied to skin, can lead to 
the activation of Langerhans cells , which subsequently 
migrates to local lymph nodes to activate the adaptive 
immune system. Other cell types activated by imiquimod 
include natural killer cells, macrophages and B-
lymphocytes.
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Thalidomide and its immunomodulatory (IMiDs) analogs 
(lenalidomide, Revlimid, CC-5013; CC-4047, ACTIMID) 
are a novel class of compounds with numerous effects on 
the body’s immune system, some of which are thought to 
mediate the anticancer and anti-inflammatory results 
observed in humans. Thalidomide is currently being used 
experimentally to treat various cancers and inflammatory  
diseases. It is approved for the treatment of dermal 
reaction from leprosy and is currently in phase III trials for 
multip le myeloma. Thalidomide and IMiDs inhibit the 
cytokines tumor necrosis factor- α (TNF-α), interleukins 
(IL) 1β, 6, 12, and granulocyte macrophagecolony 
stimulat ing factor (GM-CSF). They also costimulate 
primary human T lymphocytes inducing their proliferation, 
cytokine production, and cytotoxic activity thereby 
increasing the T cells’ anticancer activ ity. They induce an 
IL-2-mediated primary T cell proliferation with a 
concomitant increase in IFN-γ production and decrease the 
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density of TNF-α−induced cell surface adhesion molecules 
ICAM-1, VCAM-1, and E-selectin on human umbilical 
vein endothelial cells. Thalidomide stimulates the Th-1 
response increasing IFN-γ levels while CC-4047 increased 
IL-2 as well. Some of the above immunomodulatory 
activities along with anti-angiogenic, anti-proliferative, 
and pro-apoptotic properties are thought to mediate the 
IMiDs’antitumor responses observed in relapsed and 
refractory mult iple myeloma and some solid tumor 
cancers. This has led to their use in various oncology 
clin ical trials. The second generation IMiD, lenalidomide, 
has shown potential in treating the bone marrow disorders  
myelodysplastic syndrome and mult iple myeloma. It is 
currently in phase II and III trials for these diseases 
respectively with numerous  phase II trials in other 
hematologic and solid tumors .
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Figure 4: Sites of activity of thalidomide and IMiDÒs in the bone marrow of mult iple myeloma Patients
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Figure 5: Structures of thalidomide, lenalidomide and CC-4047 
9-fluorenon-4-carboxamides  has been prepared as 
asymmetrically-substituted analogues of the antiviral 
tilorone and their antiherpetic and cytokine-inducing 
properties have been exp lored. The best pharmacological 
profiles were shown by carboxamides 1, 4, 9, and 10 
endowed with anti-HSV-2, IFNα, IFNγ and TNFα-
inducing properties assayed on peripheral blood 
mononuclear cells (PBMC). The conformational analysis 
of compounds 1-10 has been performed by molecu lar 
modelling techniques and a geometrical descriptor was 
evaluated. 
 
Figure 6: Tilorone 
Scheme shows the synthetic pathway used for the 
preparation of 4-carboxamides 1-10 (Table3) starting from 
commercial 9-fluorenon-4-carbonyl chloride by 
condensation with selected primary amines, in presence of 
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distilled t riethylamine, in dich loromethane for 24h. An 
improvement of hydrosolubility was due to amines 
endowed with different basic chains bearing OH groups or 
nitrogen and oxygen atoms which help in DNA-
intercalation or to stabilize it.  
 
 
Scheme 
Table 3: 9 -flurenon-4-carboxamides 
 
A new series of tilorone like compounds, based on various 
substitutions in position 4 on the 9-fluorenone skeleton, 
has been proposed as potential anti-HSV-2 agents. 
Synthesis and chemicalphysical characterization have been 
coupled with a conformat ional analysis focusing on the 
tricyclic surface exposed to the solvent and potentially able 
to make intercalation in the DNA duplex.  
Moreover the pharmacological evaluation demonstrated 
that carboxamides 1, 4, 9 and 10, inducing cytokines such 
as IFN-γ, IFN-α, and TNF-α, p lay beneficial ro les against 
virus replicat ion.
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Murabutide, has been found to enhance the host’s 
nonspecific resistance to bacterial and viral infections, to 
induce colony-stimulat ing activity, and to be well tolerated 
by humans. In contrast to most other exogenous 
immunomodulators, Murabutide is apyrogenic, does not 
induce inflammatory reactions and has the capacity to 
synergize with selected therapeutic cytokines to drive the 
release of T-helper 1 cytokines. Moreover, the co-
administration of Murabutide with alpha interferon (IFN-a) 
or with interleukin-2 (IL-2), was found to dramatically  
enhance the antitumor activ ity of either cytokine, as well 
as the antiviral and anti-inflammatory effects of IFN-a. 
Furthermore, Murabutide presents a highly interesting 
immunopharmacological p rofile with its ability to regulate 
macrophage function.
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The mechanis ms of action of Murabutide: In conclusion, 
several independant studies and others allow us to 
determine the mechanism of biological activ ities of the 
immunomodulator Murabutide. 
Interaction of the non-specific immunomodulator 
Murabutide with human leukocytes results in the 
regulation of cellular genes leading to: 
 Enhanced resistance to viral and bacterial infections  
 Inhibition of v iral replication in infected cells  
 Potentiation of antiviral, antitumor and anti-
inflammatory activit ies of therapeutic cytokines (IFN-
alpha; IL-2) 
 Restoration of defective antigen-presenting cell 
function in macrophages and dendritic cells  thereby 
leading to efficacious adaptive immunity  
 Restoration of selective cytokine milieu which drives 
protective Th-1 responses against intracellular 
infections and tumor 
Regulated cellular factors in Lymphocytes (HIV -
related): 
 Inhibition of the expression of c- myc: the cellu lar 
factor required for the nuclear transport of HIV pre- 
integration complexes 
 Inhibition of the expression of RH116: a novel RNA 
helicase necessary for HIV t ranscription 
 Induction of the release of HIV-suppressive 
chemokines. 
Regulated cellular factors in macrophages (HIV-related): 
 Selective induction/activation of transcription factors 
capable of inhib iting HIV-1 LTR. 
 Induction of the release of HIV-suppressive beta 
chemokines. 
 Inhibition of the expression of HIV-1 co-receptors 
CXCR4 and CCR5. 
Regulated cellular factors mediating other biological 
effects of Murabutide: 
 Up-regulation of HSP 70 as mediator of adjuvant 
effect. 
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 Induction of IL-1 receptor antagonist, IL-1 receptor 
accessory protein, and soluble TNF receptors as 
mediators of the anti- inflammatory activity. 
 Induction of BMP-8 (bone morphogenetic protein 8) 
and IGFBP-5 (Insulin - like growth factor b inding 
protein 5) as protential mediators of accelarated bone 
formation. 
 Induction of NINJ-1 and LICAM as mediators of 
nerve regeneration. 
 Up-regulation of Toll- like receptors and LRP-5 as 
mediators of enhanced innate immunity against viral 
and bacterial infections. 
 Activation of transcription factors stat-1 and IRF-2 as 
mediators of Th-1 responses and enhanced antiviral 
activity of IFN-alpha. 
 Up-regulation of CD40, MHC-II, CD80 and CD86 as 
receptors implicated in dendritic  cell- T cell 
interaction, leading to efficacious adaptive immune 
responses. 
Leflunomide is a medication of the DMARD type, used in 
active moderate to severe rheumatoid arthrit is  and psoriatic 
arthritis. It is a pyrimidine synthesis inhibitor. 
Leflunomide is a pyrimid ine synthesis inhibitor belonging 
to the DMARD (disease-modifying antirheumatic drug) 
class of drugs, which are chemically and 
pharmacologically very heterogeneous. The chemical 
name for leflunomide is N-(4'-trifluoromethylphenyl)-5-
methylisoxazo le-4-carboxamide. Leflunomide is an 
immunomodulatory drug inhibiting dihydroorotate 
dehydrogenase (an enzyme involved in de novo pyrimidine 
synthesis). Genuine antiproliferat ive activity has been 
proven. Additionally, several experimental models (both in 
vivo and in vitro) have demonstrated an anti-inflammatory  
effect. This double action is supposed to slow progression 
of the disease and to cause remission/relief of symptoms of 
rheumatoid arthrit is  and psoriatic arthritis such as joint 
tenderness and decreased joint and general mobility in  
human patients.
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Contraindications and Precautions  
 
Leflunomide  
Leflunomide has a great number of absolute and relative 
contraindications, in part associated with its mode of 
action: 
 Hypersensitivity to the drug or to inactive ingredients 
(e.g., lactose).  
 Important contraindications are preexisting pregnancy, 
or women of childbearing potential not using reliable 
anticonceptive methods.  
 Preexisting significant liver or renal disease and 
moderate to severe diseases of the bone marrow or 
immune system preclude the use of Leflunomide.  
 Moderate to severe bacterial, fungal or viral infections 
(e.g., AIDS, latent HIV-Infect ion, pneumonia, active 
tuberculosis).  
 Combination with methotrexate, other DMARDs and 
alcohol.  
Side-Effects: 
The side-effects of Arava affect quite a number of organ 
systems, are frequent and at times severe or even fatal.  
Most serious is symptomatic liver damage ranging from 
jaundice to hepatitis, which can be fulminant, severe liver 
necrosis, and liver cirrhosis. Also very important is a 
relatively high incidence of myelosuppression with 
leukopenia, and/or hypoplastic anemia, and/or 
thrombocytopenia. Infect ions, sometimes as severe as 
development of active tuberculosis, pneumonia, PCP, and 
severe viral or mycotical in fections, possibly leading to 
sepsis, death or permanent damage have been seen. 
Anemia or bleeding episodes may also lead to serious 
complications.  
Interactions: 
Alcohol, other DMARDs including 
chloroquine/hydroxychloroquine, live virus vaccines, 
tegafur, some tuberculostatics (rifampin and/or isoniazid), 
tolbutamide and warfarin should not be given 
concomitantly.  
CONCLUS ION:  
Most immune syndromes are caused by a deregulation in 
an auto regulating system. Conventional suppressive 
approach will o ften induce a switch of the balance, which  
means that the one rigidity is replaced by a new one, 
induced by the immunosuppressive medication itself. By  
using micro doses stimuli, coming from antihomotoxic 
medications, immunomodulation is possible in such a way 
that the rigidity changes into a balancing autoregulation 
again. 
Immunomodulator can modulate immune systems in 
different ways with the use of exogenous or endogenous 
bioactive agents which utilize cell-to-cell signaling in  
order to reach homeostasis within an organism's innate 
cellu lar defense. Although immunomodulators are 
commonly thought to be suppressive agents, such 
biological act ivists are well known to offer 
immunostimulation. An ext remely complex cellu lar 
symphony of signaling regulates an organism's 
immunostatus through immunomodulators. 
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